Table 1.
MiRNAs with diagnostic and prognostic value and their targets in malignant mesothelioma.
| miRNA | Target genes | Cell function | References | ||
|---|---|---|---|---|---|
| DIAGNOSIS | miR-16 | Bcl-2, CCND1 | Apoptosis, cell cycle | (115, 116) | |
| miR-103 | ICOS, SERBP1, FBXW11 | Transcription, genome integrity | (117) | ||
| miR-106 | Unknown | – | (118) | ||
| miR-223 | PARP1, MDM2, TP53, JNK signaling, STMN1 | Cell motility, tubulin acetylation | (119) | ||
| miR-625 | Unknown | – | (120) | ||
| PROGNOSIS-DIAGNOSIS | miR-17 | KCNMA1 | Cell migration | (115, 121) | |
| miR-193a | MCL1, PD-L1, E2F1, SRSF2, TYMS | Proliferation, apoptotic/necrotic | (122) | ||
| miR-143 | DNMT3A, FOSL2 | Proliferation, methylation | (82) | ||
| miR-652 | Unknown | – | (82) | ||
| miR-23a | Unknown | – | (113) | ||
| miR-31 | PPP6C | Proliferation, migration, invasion, colony formation | (55–57, 113) | ||
| Epi-miRNA | miR-34 | c-MYC, c-MET, BCL-2, CDKN2, NF2, TP53 | Proliferation, invasion, migration apoptosis, differentiation | (59–62) | |
| miR-145 | OCT4, ZEB1 | Proliferation, invasion, migration, angiogenesis | (63, 64, 82) | ||
| miR-126 | CRK, PI3K/Akt, p85β, IRS1, ADAM9, VEGF, VCAM1, EGFL7, SOX-2 | Proliferation, invasion, migration, angiogenesis | (65, 82, 90) | ||
| PROGNOSIS | miR-29c | DNMT1, DNMT3A | Proliferation, migration, invasion, colony formation, methylation | (106, 107) | |
| miR-21 | PARP1, MSLN | DNA repair | (113, 123, 124) | ||
| miR-30 | P53 | Tumor suppressor, cell cycle | (113) | ||
| miR-221/222 | PTEN, TIMP3, p27Kip1, p57, Bim | Cell invasion, metastasis | (113, 125) |
CCND1, cyclin D1-encoding gene; ICOS, inducible T-cell co-stimulator; SERBP1, SERPINE1 MRNA Binding Protein 1; FBXW11, F-box and WD repeat domain containing 1; PARP1, Poly(ADP-ribose) polymerase-1; MDM2, Mouse double minute 2 homolog; STMN1, Stathmin 1; KCNMA1, calcium-activated potassium channel subunit alpha 1; PD-L1, Programmed death-ligand 1; E2F1, E2F Transcription Factor 1; SRSF2, Splicing factor, arginine/serine-rich 2; TYMS, Thymidylate Synthetase; DNMT3A, DNA methyltransferase-3A, FOSL2, Fos-related antigen 2; PPP6C, Protein Phosphatase 6 Catalytic Subunit; CDKN2, cyclin-dependent kinase inhibitor; NF2, neurofibromatosi tipo 2; OCT-4, octamer-binding transcription factor 4; ZEB1, Zinc Finger E-Box Binding Homeobox 1; IRS1, insulin receptor substrate-1; ADAM9, metalloproteinase domain-containing protein 9; VEGF, vascular endothelial growth factor; VCAM1, vascular cell adhesion molecule 1; EGFL7, epidermal growth factor-like domain-containing protein 7; SOX-2, Sex-determining region Y-box 2; MSLN, mesothelin; PTEN, prime time entertainment network; TIMP3, TIMP metallopeptidase Inhibitor 3.